Recruiting Clinical Trials
Institute | Protocol No. | Trial name | Cancer Site | Experimental Treatment Agent | Key Eligibility Criteria | Principal Investigator | Study Coordinator Contact |
---|---|---|---|---|---|---|---|
HKU |
20210023 UW 22-014 CTC2265 |
A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors |
1. squamous cell NSCLC 2. adenocarcinoma 3. NSCLC cholangiocarcinoma 4. HNSCC 5. pancreatic 6. adenocarcinoma solid tumor, exclusive of squamous or adenocarcinoma NSCLC, cholangiocarcinoma, HNSCC, pancreatic adenocarcinoma, primary brain tumor, and lymphoma |
AMG 193 alone and in combination with docetaxel |
1. Adults (>=18 years old) with advanced MTAP-null solid tumors 2. Histologically confirmed metastatic or locally advanced solid tumor not amenable to curative treatment with surgery and/or radiation 3. Disease measurable as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) 4. Tumor tissue sample must be available (either fresh or achieved) |
Dr. Aya El Helali |
Stephen AU (main) |
HKU |
61186372NSC3002 |
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure |
Locally advanced/Metastatic NSCLC |
Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed |
1. Participant must have histologically or cytologically confirmed, locally advanced or metastatic, non-squamous NSCLC, characterized at or after the time of locally advanced metastatic disease diagnosis by either EGFR Exon 19del or Exon 21 L858R mutation. |
Dr. Victor LEE |
Angela IU |
HKU |
AN2025H0301 |
The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
Buparlisib + Paclitaxel vs. Paclitaxel |
1. Patient has histologically and/or cytologically-confirmed HNSCC. |
Dr. Victor LEE |
Angela IU |
HKU |
ARC-10 |
A Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB 154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Locally Advanced / Metastatic NSCLC |
Zimberelimab (AB 122) |
1. Histologically confirmed, treatment naïve, locally advanced or metastatic (Stage IIIB - IV), squamous or non-squamous NSCLC with documented high PD-L1 Expression |
Dr Victor LEE |
Vera WONG |
HKU |
FOLFOXIRI and CRT for high risk rectal cancer UW 21-577 |
A randomized study of neoadjuvant chemoradiotherapy with or without intensification with the FOLFOXIRI chemo-regimen for high-risk locally advanced rectal cancer |
Rectal adenocarcinoma |
1. Arm A (control): Concurrent neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and post-operative chemotherapy 2. Arm B (experimental): Neoadjuvant FOLFOXIRI x 4 cycles then concurrent capecitabineradiotherapy, surgery and post-operative chemotherapy |
1. Histologically confirmed rectal adenocarcinoma (defined as either mid- or low rectal cancer that is located within 12 cm from the anal verge OR below the peritoneal reflection) that is previously untreated. 2. Measurable disease by RECIST 1.1 criteria. 3. ‘High-risk’ rectal cancer, or rectal cancers that are considered marginally operable where there is a significant risk of ‘positive surgical margin’ (or otherwise known as ‘threatened circumferential margin’) = T3 or T4 tumor with one or more of the following features: |
Dr. Aya El Helali |
Stephen AU |
HKU |
VT3996-301 |
An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma |
Recurrent/Metastatic Nasopharyngeal Carcinoma |
Nanatinostat + Valganciclovir |
1. Histologically or cytologically documented EBV+ tumor cells by EBER-ISH or LMP-1 per an archival tumor sample taken within 2 years prior to screening, otherwise a de novo biopsy is required. |
Dr. Victor LEE |
Angela IU |
HKU |
Cullinan-Pearl |
A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations |
NSCLC |
CLN-081 |
1. Documented EGFR exon 20 insertion mutation demonstrated by a test routinely used by each institution and performed in a CLIA-certified or equivalent laboratory. |
Dr Victor LEE |
Angela IU 2255 5124 |
HKU |
DS8201-A-U305 |
A Phase 3, Multicenter, Randomized, Open-Label, |
HER2+ BC |
Trastuzumab deruxtecan (T-DXd) |
1. Pathologically documented HER2-positive breast cancer (BC) |
Dr Wendy CHAN |
Emina CHEUNG |
HKU |
DS8201-A-U306 |
A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive metastatic and/or unresectable gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04) |
Gastric/GEJ (2nd line) |
Trastuzumab deruxtecan vs |
1. Progression on or after first-line therapy with a trastuzumab or approved trastuzumab biosimilar-containing regimen |
Dr Wendy Chan |
Michael WONG 2255 4216 |
HKU |
A multi-centre phase II randomized-controlled study on addition of durvalumab (MEDI4736) to induction chemotherapy and concurrent chemoradiation and followed by maintenance durvalumab for locoregionally advanced nasopharyngeal carcinoma |
NPC |
Durvalumab |
1. Previously untreated stage III-IVA nasopharyngeal carcinoma |
Dr Victor LEE |
Mike LAW 2255 5124 |
|
HKU |
A multi-centre single-arm phase II study on durvalumab (MEDI 4736) with stereotactic body radiation therapy (SBRT) in patients with inoperable/unresectable hepatocellular carcinoma |
inoperable / unresectable hepatocellular carcinoma |
Durvalumab with SBRT |
1. Histologically or radiologically confirmed HCC |
Dr Victor LEE |
Mike LAW 2255 5124 |
|
HKU |
MK-3475-975 |
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975) |
Esophageal Carcinoma |
Pembrolizumab + Chemoradiotherapy |
1. Receiving concurrent definitive chemoradiotherapy |
Prof Dora KWONG |
Bryan Yun |
HKU |
MK7902-014 |
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma |
Metastatic Esophageal Carcinoma |
Pembrolizumab + Lenvatinib + Chemotherapy vs Pembrolizumab + Chemotherapy |
1. Metastatic squamous cell carcinoma of the esophagus |
Professor Dora KWONG |
Bryan Yun |
HKU |
MK-7902-015 |
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015) |
advanced/metastatic gastroesophageal cancer |
Lenvatinib + CAPOX/mFOLFOX6 vs CAPOX/mFOLFOX6 |
1. Previously untreated, locally advanced unresectable / metastatic gastroesophageal adenocarcinoma |
Dr Chan Wing Lok Wendy |
Michael WONG 2255 4216 |
hku |
OBI-822-011 |
|
TNBC |
Adagloxad Simolenin + OBI-821 |
|
Dr Wendy CHAN |
Bryan Yuan |
HKU |
TAS-102 |
Phase II Trial of TAS-102 in Patients with Advanced, Refractory Pancreatic Adenocarcinoma |
Pancreatic Cancer |
TAS-102 |
1. Histological or cytological confirmed advanced or metastatic pancreatic cancer |
Dr CHIANG Chi Leung |
Isabel CHAN |
HKU |
TAC-GReD |
Combination Talazoparib - carboplatin for recurrent high-grade glioma with DNA damage repair deficiency (DDRd) “TAC-GReD” trial |
high-grade glioma |
Talazoparib + carboplatin |
Recurrent high grade glioma with DDRd, defined by genomic aberrations associated including IDH mutation, PTEN mutation and “BRCAness” signature (ATM, ATR, BAP1, BRCA1, BRCA2, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, PALB2, NGS1, WRN, RAD50, RAD51B, RAD51C, RAD51D, MRE11A, BLM, BRIP1) |
Dr. Aya El Helali |
Stephen AU 2255 5034 |
HKU |
UW 19-565 |
Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer Patients |
All cancer types |
Any kind of therapy or healthy control |
1. Cancer Patients: • 18 years of age and older. • Scheduled to receive any kind of therapy or no cancer therapy • ECOG Performance score of 0, 1, 2, or 3. • Able to understand QoL questionnaire 2. Normal (non cancer) controls • 18 years of age and older healthy volunteers. • Without a history of cancer except for cured skin cancer • ECOG Performance status 0, 1, 2, or 3. |
Professor Feng-ming Spring KONG |
Eunice Xie 22555123 |